Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderLimited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
CD70 VHH - 01 | Lead | Hematological Malignancy | Non-hodgkin lymphoma |
5e5 of 293 CAR cells transfected with anti-CD27 Ligand-scFv were stained with 100 μL of 3 μg/mL of Alexa Fluor 555-Labeled Human CD27 Ligand Protein, His Tag (Cat. No. CDL-HA245) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A), Alexa 555 signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-CD27 Ligand Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) with a linear range of 0.039-0.156 μg/mL (QC tested).
The purity of FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) is more than 85% and the molecular weight of this protein is around 55-74 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AMG-172 | AMG-172 | Amgen Inc | Details | ||
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
MDX-1203 | BMS-936561; MDX-1203 | Bristol-Myers Squibb Company | Details | ||
SEA-CD70 | SEA-CD70 | Phase 1 Clinical | Seattle Genetics Inc | Leukemia, Myeloid, Acute | Details |
Vorsetuzumab mafodotin | SGN-75 | Seattle Genetics Inc | Details | ||
GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Ambrx Inc, Zhejiang Xinma Biomedicine Co Ltd | Neoplasms | Details |
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics Ag | Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details | |
IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Allogene Therapeutics Inc | Carcinoma, Renal Cell | Details |
This web search service is supported by Google Inc.